NS Pharma Reports on Results of VILTEPSO® (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy ...Middle East

Results were from a final analysis (up to Week 216) of the open-label extension trial of a VILTEPSO Phase 2 study. In the study, the primary endpoint of Time to Stand and secondary endpoints, including Time to Run/Walk and Time to Climb 4 Stairs, were evaluated in comparison to a...

Hence then, the article about ns pharma reports on results of viltepso viltolarsen injection after four years of treatment in open label extension trial in duchenne muscular dystrophy was published today ( Monday 24/10/2022 - 04:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NS Pharma Reports on Results of VILTEPSO® (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy )

Also on site :

• Nuclear neighbors and a two‑front threat: Why India needs a rocket force
• 2010s Rock Band Announces Tour for 10th Anniversary of Debut Album
• Greenland hit by power outage, strong winds in wake of US tensions easing